Praxis Precision Medicines reported that its oral small molecule ulixacaltamide met primary endpoints in two pivotal Phase 3 trials for essential tremor. The company said the dual wins support plans for a new drug application and followed large, multi-center programs that enrolled several hundred patients. Investors reacted sharply to the data, reflecting the unmet need in a disorder with no approved disease-modifying therapies. Ulixacaltamide is a small-molecule T‑type calcium channel inhibitor; Praxis described statistically significant improvements on activities-of-daily-living and maintenance-of-effect endpoints across the two trials. The trials’ positive results set the company up to engage regulators on an NDA timeline. T‑type calcium channels are a subtype of voltage-gated calcium channels involved in neuronal rhythmicity, relevant to tremor circuitry.